FDA is preparing to propose a ban on specific hair-straightening products, including chemical relaxers and pressing agents, due to their potential health risks.
U.S. Food and Drug Administration (FDA) is preparing to propose a ban on specific hair-straightening products, including chemical relaxers and pressing agents, due to their potential health risks.
This decision comes as recent findings have linked these products to serious health concerns, prompting calls for regulatory action.
The proposed rule, if issued, will specifically target hair-straightening products containing formaldehyde and other related chemicals like methylene or glycol. The FDA’s spokesperson, Courtney Rhodes, emphasized that the agency will welcome public comments upon the release of the proposed rule. Following a thorough review of these comments, the FDA will determine if further action, such as the issuance of a final rule, is warranted.
Scientists have long observed an association between the use of hair-straightening chemical products and an elevated risk of hormone-related cancers. Notably, this includes ovarian, breast, and uterine cancers, particularly among Black and Latina women.
Research indicates that approximately 50% of products marketed to Black women contain these chemicals, compared to only about 7% targeting White women, as reported by the Harvard T.H. Chan School of Public Health.
The FDA’s anticipated proposal will highlight that these hair-straightening products are not only linked to long-term health effects but also short-term adverse reactions, such as sensitization responses and respiratory issues. These chemicals are commonly used in cosmetic products applied to human hair, forming part of a combined chemical and heating treatment aimed at smoothing or straightening hair.
In March, Representatives Ayanna Pressley and Shontel Brown urged FDA Commissioner Dr. Robert Califf to conduct a thorough investigation into whether hair-straightening chemical products contain carcinogens associated with an increased risk of uterine cancer. Both lawmakers have praised the FDA’s intention to take action and have called for the swift implementation of the proposed ban.
Pressley expressed her support, stating, “The FDA’s proposal to ban these harmful chemicals in hair straighteners and relaxers is a win for public health – especially the health of Black women who are disproportionately put at risk by these products as a result of systemic racism and anti-Black hair sentiment.”
A recent study published in the Journal of the National Cancer Institute further substantiates the concerns. The research, involving nearly 34,000 women in the U.S., revealed a higher incidence of uterine cancer among those who reported using hair-straightening chemical products in the previous year. The risk for developing uterine cancer by age 70 was approximately 4% for frequent users, compared to 1.6% for non-users.
As discussions surrounding the potential ban on these products continue, the FDA’s decision will play a pivotal role in safeguarding public health.
The proposed rule signifies a crucial step towards addressing a longstanding concern and ensuring the well-being of consumers, particularly those disproportionately affected by these products. The FDA’s commitment to transparency and accountability in this matter is a positive development for the health and safety of individuals nationwide.